"Switching to a whole-cell pertussis priming strategy could reduce incidence of whooping cough by up to 95%, new research indicates.
Studies have widely agreed that pertussis protection from the current vaccine, tetanus toxoid, reduced"...
Prevnar® is indicated for active immunization of infants and toddlers against invasive disease caused by S. pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F). The routine schedule is 2, 4, 6, and 12-15 months of age.
The decision to administer Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Prevnar® should be based primarily on its efficacy in preventing invasive pneumococcal disease. As with any vaccine, Prevnar® may not protect all individuals receiving the vaccine from invasive pneumococcal disease.
Prevnar® is also indicated for active immunization of infants and toddlers against otitis media caused by serotypes included in the vaccine. However, for vaccine serotypes, protection against otitis media is expected to be substantially lower than protection against invasive disease. Additionally, because otitis media is caused by many organisms other than serotypes of S. pneumoniae represented in the vaccine, protection against all causes of otitis media is expected to be low. (See CLINICAL PHARMACOLOGY for estimates of efficacy against invasive disease and otitis media).
For additional information on usage, see DOSAGE AND ADMINISTRATION.
This vaccine is not intended to be used for treatment of active infection.
DOSAGE AND ADMINISTRATION
For intramuscular injection only. Do not inject intravenously.
The dose is 0.5 mL to be given intramuscularly.
Since this product is a suspension containing an adjuvant, shake vigorously immediately prior to use to obtain a uniform suspension in the vaccine container. The vaccine should not be used if it cannot be resuspended.
After shaking, the vaccine is a homogeneous, white suspension.
The vaccine is not to be mixed with other vaccines/products in the same syringe.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration (see DESCRIPTION). This product should not be used if particulate matter or discoloration is found.
The vaccine should be injected intramuscularly. The preferred sites are the anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in toddlers and young children. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel. Before injection, the skin at the injection site should be cleansed and prepared with a suitable germicide. After insertion of the needle, aspirate and wait to see if any blood appears in the syringe, which will help avoid inadvertent injection into a blood vessel. If blood appears, withdraw the needle and prepare for a new injection at another site.
For infants, the immunization series of Prevnar® consists of three doses of 0.5 mL each, at approximately 2-month intervals, followed by a fourth dose of 0.5 mL at 12-15 months of age. The customary age for the first dose is 2 months of age, but it can be given as young as 6 weeks of age. The recommended dosing interval is 4 to 8 weeks. The fourth dose should be administered at approximately 12-15 months of age, and at least 2 months after the third dose.
Vaccination schedule for infants and toddlers
|Dose:||Dose 1*†||Dose 2†||Dose 3†||Dose 4‡|
|Age at Dose:||2 months||4 months||6 months||12-15 months|
|* Dose 1 may be given as early
as 6 weeks of age.
† The recommended dosing interval is 4 to 8 weeks.
‡ The fourth dose should be administered at approximately 12-15 months of age, and at least 2 months after the third dose.
Previously Unvaccinated Older Infants and Children
For previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, the following schedule applies:31
Vaccine schedule for previously unvaccinated children
≥ 7 months of age
|Age at First Dose||Total Number of 0.5 mL Doses|
|7-11 months of age||3*|
|12-23 months of age||2†|
|> 24 months through 9 years of age||1|
|* 2 doses at least 4 weeks
apart; third dose after the one-year birthday, separated from the second dose
by at least 2 months.
† 2 doses at least 2 months apart.
(See CLINICAL PHARMACOLOGY section for the limited available immunogenicity data and ADVERSE REACTIONS section for limited safety data corresponding to the previously noted vaccination schedule for older children).
Safety and immunogenicity data are either limited or not available for children in specific high risk groups for invasive pneumococcal disease (eg, persons with sickle cell disease, asplenia, HIV-infected).
Syringe, 1 Dose (10 per package) - NDC 0005-1970-50
CPT Code 90669
DO NOT FREEZE. STORE REFRIGERATED, AWAY FROM FREEZER COMPARTMENT, AT 2°C TO 8°C (36°F TO 46°F).
This product's label may have been updated. For current package insert and further product information, please visit www.wyeth.com or call our medical communications department toll-free at 1-800-934-5556.
31. Lederle Laboratories, Data on File: Integrated Summary on Catch-Up.
Manufactured by: Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101. Revised: 10/08This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/16/2015
Additional Prevnar Information
Prevnar - User Reviews
Prevnar User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.